To include your compound in the COVID-19 Resource Center, submit it here.

Actimmune: Phase III

Exploratory analysis from follow-up of a placebo-controlled, double-blind international Phase III trial in 330 patients

Read the full 158 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE